Oppenheimer Holdings Stock News

Oppenheimer (NYSE: OPY) is one of 53 public companies in the Security brokers & dealers industry, but how does it weigh in compared to its peers? We will compare Oppenheimer to similar companies based on the strength of its analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership. Valuation and Earnings This table compares []

127619 (MDN.TO) (TSE:MDN) Analysts at Oppenheimer cut their Q3 2022 EPS estimates for shares of 127619 (MDN.TO) in a research report issued on Monday, November 15th. Oppenheimer analyst M. Biegler now forecasts that the mining company will post earnings per share of ($0.14) for the quarter, down from their previous forecast of ($0.12). Oppenheimer []

CYBIN INC. (CYBN.NE) (OTCMKTS:CYBN) Oppenheimer lowered their Q3 2022 earnings per share (EPS) estimates for CYBIN INC. (CYBN.NE) in a research report issued on Tuesday, November 16th. Oppenheimer analyst F. Brisebois now expects that the company will earn ($0.09) per share for the quarter, down from their previous forecast of ($0.07). Oppenheimer currently has []

Rezolute, Inc. (NASDAQ:RZLT) Equities researchers at Oppenheimer lifted their Q2 2022 EPS estimates for Rezolute in a report released on Monday, November 15th. Oppenheimer analyst K. Degeeter now anticipates that the company will post earnings of ($0.66) per share for the quarter, up from their prior estimate of ($0.91). Oppenheimer also issued estimates for []

Angion Biomedica Corp. (NASDAQ:ANGN) Equities researchers at Oppenheimer raised their FY2021 earnings per share (EPS) estimates for Angion Biomedica in a report released on Monday, November 15th. Oppenheimer analyst J. Kim now forecasts that the company will post earnings of ($3.20) per share for the year, up from their prior forecast of ($3.52). Oppenheimer []

89bio, Inc. (NASDAQ:ETNB) Stock analysts at Oppenheimer dropped their FY2021 EPS estimates for shares of 89bio in a research note issued on Monday, November 15th. Oppenheimer analyst J. Olson now forecasts that the company will post earnings per share of ($4.71) for the year, down from their prior estimate of ($4.05). Oppenheimer also issued []

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Research analysts at Oppenheimer decreased their FY2021 earnings per share estimates for shares of IDEAYA Biosciences in a research note issued on Monday, November 15th. Oppenheimer analyst K. Degeeter now forecasts that the company will earn ($1.24) per share for the year, down from their previous estimate of ($1.22). Oppenheimer []

Workday (NASDAQ:WDAY) had its target price hoisted by Oppenheimer from $285.00 to $340.00 in a report released on Monday, The Fly reports. The firm currently has an outperform rating on the software makers stock. Oppenheimer also issued estimates for Workdays Q3 2022 earnings at ($0.02) EPS. Several other equities analysts also recently commented on the []

Mustang Bio, Inc. (NASDAQ:MBIO) Research analysts at Oppenheimer decreased their FY2021 EPS estimates for shares of Mustang Bio in a research note issued on Tuesday, November 16th. Oppenheimer analyst M. Breidenbach now anticipates that the company will earn ($0.72) per share for the year, down from their previous estimate of ($0.66). Oppenheimer also issued []

Exact Sciences Co. (NASDAQ:EXAS)s share price reached a new 52-week low during trading on Thursday . The company traded as low as $85.61 and last traded at $86.38, with a volume of 29171 shares changing hands. The stock had previously closed at $88.38. A number of analysts have recently commented on the company. Oppenheimer cut []

Christopher Nolans next movie Oppenheimer, a $100 million-budgeted historical drama about physicist J. Robert Oppenheimer and the creation of the atomic bomb, could be considered one of an endangered species. These days, its rare for traditional studios to pump nine figures into a film that isnt inspired by popular toys, novels or comic books. Even []

Jessica Slack-Jell and Rebecca Oppenheimer, the granddaughters of industrialist Harry Oppenheimer, gave ActionSA multimillion-rand donations for the November 1 polls.

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Stock analysts at Oppenheimer decreased their FY2021 earnings per share estimates for PMV Pharmaceuticals in a report released on Monday, November 15th. Oppenheimer analyst J. Jones now forecasts that the company will post earnings per share of ($1.22) for the year, down from their previous forecast of ($1.14). Oppenheimer has []

Gamida Cell (NASDAQ:GMDA) had its target price lowered by Oppenheimer from $17.00 to $15.00 in a report issued on Tuesday morning, The Fly reports. The brokerage currently has an outperform rating on the stock. Several other analysts have also issued reports on the company. Alliance Global Partners started coverage on Gamida Cell in a research []

Isoray, Inc. (NYSEAMERICAN:ISR) Equities research analysts at Oppenheimer lowered their FY2022 earnings per share estimates for Isoray in a research note issued to investors on Thursday, November 11th. Oppenheimer analyst S. Kalia now forecasts that the healthcare company will post earnings of ($0.04) per share for the year, down from their previous estimate of []